MK-2206 Not Effective in Gastric, Gastroesophageal Junction Cancers

Share this content:
MK-2206 was well tolerated in gastric or gastroesophageal junction cancers as second-line therapy, but did not demonstrate sufficient activity.
MK-2206 was well tolerated in gastric or gastroesophageal junction cancers as second-line therapy, but did not demonstrate sufficient activity.

MK-2206, an AKT inhibitor, was well tolerated by patients with gastric or gastroesophageal junction cancers as second-line therapy, but it did not demonstrate sufficient activity, a recent study published online early in the journalCancer has shown.

For the phase II study, researchers sought to evaluate the use of MK-2206 as second-line therapy in patients with gastric or gastroesophageal junction cancers. Researchers enrolled 70 patients and all patients received MK-2206 60mg orally every other day.

Results showed a response rate of 1%. Researchers found that the median progression-free survival was 1.8 months (95% CI: 1.7-1.8) and the median overall survival was 5.1 months (95% CI: 3.7-9.4).

In regard to safety, the most common grade 3 adverse event was fatigue and the most common grade 4 adverse events were anemia, hyperglycemia, and lung infection.

RELATED: Docetaxel and 5-Fluorouracil: Promising Novel Regimen for Advanced Gastric Cancer

The most common all grade adverse events included fatigue, nausea, anorexia, hyperglycemia, macropapular rash, diarrhea, vomiting, dry skin, anemia, and aceniform rash.

Because the response rate was observed to be low, the authors conclude that MK-2206 should not be further tested in this population.

Reference

  1. Ramanathan RK, McDonough SL, Kennecke HF, et al. Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: a SWOG cooperative group trial (S1005). Cancer. 2015. [Epub ahead of print]. doi: 10.1002/cncr.29363.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs